TRCT
MREO

Tower Research Capital (TRC)’s Mereo BioPharma MREO Stock Holding History

Tower Research Capital (TRC)’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-645
Closed -$2.65K – 5890
2024
Q3 		$2.65K Buy
+645
New +$2.67K ﹤0.01% 4956
2024
Q2 		– Sell
-7,145
Closed -$23.6K – 5890
2024
Q1 		$23.6K Buy
+7,145
New +$24.2K ﹤0.01% 2852
2023
Q1 		– Sell
-15,129
Closed -$11K – 6110
2022
Q4 		$11K Buy
15,129
+2,562
+20% +$2.1K ﹤0.01% 3846
2022
Q3 		$11K Buy
12,567
+233
+2% +$285 ﹤0.01% 4453
2022
Q2 		$14K Buy
12,334
+12,273
+20,120% +$9.51K ﹤0.01% 4151
2022
Q1 		$0 Sell
61
-33,620
-100% -$43.5K ﹤0.01% 6385
2021
Q4 		$54K Buy
33,681
+33,052
+5,255% +$66.1K ﹤0.01% 2711
2021
Q3 		$2K Buy
+629
New +$1.67K ﹤0.01% 5274
2019
Q4 		– Sell
-1,738
Closed -$5K – 4072
2019
Q3 		$5K Buy
1,738
+945
+119% +$2.86K ﹤0.01% 3314
2019
Q2 		$2K Buy
+793
New +$3.47K ﹤0.01% 3287

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s MREO Position: Q4 2024 in Review

Tower Research Capital (TRC) sold out of Mereo BioPharma (MREO) in Q4 2024, closing a stake of 645 shares — an estimated $2.65K sold.

Tower Research Capital (TRC) first reported a position in MREO in Q2 2019 and held it in 10 quarters. The position peaked at $54K in Q4 2021. 91 funds tracked by Wall St. Rank hold MREO as of Q4 2024.

  • Tower Research Capital (TRC) reported no remaining Mereo BioPharma position as of Q4 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 645 Mereo BioPharma shares in Q4 2024, an estimated $2.65K.
  • Tower Research Capital (TRC) first reported a position in Mereo BioPharma in Q2 2019 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Mereo BioPharma position peaked at $54K in Q4 2021.
  • 91 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.